Rats received intracisternal I8Hjnorepi-nepirine and, after 5 min, intraperitoneal L-dopa (100 mg/kg); they were killed at intervals during the subsequent 24 hr. Their brains were assayed for norepinephrine, L-dopa, S-adenosylmethionine, and These changes were all transient, lasting about 1 hr and coinciding with the period when appreciable amounts of L-dopa were detectable in the brain.
The initial enzymatic reaction in the biosynthesis of brain catecholamines involves the formation of the catechol amino acid idihydroxyphenylalanine (idopa) from ityrosine. Once formed, the L-dopa is immediately decarboxylated to form dopamine, which, in some neurons, is further transformed to norepinephrine (1, 2) . Dopa cannot be detected normally in the brain or in the blood (3) , and thus it is unlikely that circulating dopa is a physiological precursor for brain catecholamines. However, when exogenous L-dopa is administered to experimental animals, the concentration of dopamine in the brain increases (4, 5) . This observation, coupled with the finding that dopamine concentrations measured at autopsy in brains of patients with Parkinson's disease are low (6) , suggested that exogenous idopa might be useful in the treatment of Parkinsonism. That hypothesis has now been confirmed in numerous clinical studies (7) (8) (9) .
However, the importance of the conversion of L-dopa to brain dopamine as the basis of its therapeutic action remains unclear. Recent studies in mice have shown that <0.1% of injected labeled idopa is detectable as brain catecholamines at any time after administration of the amino acid (10) . i-Dopa is also known to influence the fates of other putative brain neurotransmitters in addition to dopamine. Its administration is followed by a reduction of brain serotonin concentration (11, 12) , possibly because the dopamine formed in tivo competes with serotonin for intraneuronal storage sites (13) ; moreover, some (5, 14, 15) but not all (12) observers have reported increased concentrations of brain norepinephrine after idopa administration.
If experimental animals are given doses of idopa similar to those used in the treatment of Parkinson's disease, a major portion of the administered catechol amino acid is rapidly metabolized by O-methylation to form 3-0-methyl-dopa and the 3-O-methylated and deaminated product of dopamine, homovanillic acid (10) . A marked decrease in the brain concentration of the methyl donor S-adenosylmethionine (SAMe) is found during the hour after L-dopa administration (16) . This suggests that large amounts of SAMe are utilized in the formation of these methylated compounds. If that is so, L-dopa administration might interfere with a large number of methylation reactions in which SAMe serves as the methyl donor. One such reaction of major physiological significance is the inactivation of tissue catechols by 3-0-methylation (1) In an acute experiment, animals were lightly anesthetized with ether, and 12 ,uCi of [3H]dl-norepinephrine was injected intracisternally. After 5 min, animals were given L-dopa or its diluent (0.05 N HCl) intraperitoneally, and 50 min later they were killed. Another group of rats was killed 5 min after the intracisternal injection, without receiving -dopa or the diluent, so that we could monitor the uptake of labeled amine and have an initial reference or "zero time" point for the disappearance of tritiated material. Whole brains were removed immediately after death, weighed, homogenized, and assayed for dopa, norepinephrine, and ['H]-norepinephrine and its metabolites.
In a chronic experiment, animals were given L-dopa or the acid vehicle daily for 10 days. 24 hr after the tenth injection they were given 8 ,uCi of ['H]I-norepinephrine intracisternally, followed 5 min later by intraperitoneal injection of idopa or its diluent as before. Animals were killed at 50 min, or 3, 6, or 12 hr after the intraperitoneal injection.
L-Dopa and Brain Norepinephrine 663 "Zero time" groups of rats (not given an intraperitoneal injection for 24 hr) were again obtained 5 min after the intracisternal injection. Brains were immediately removed and dissected over ice into left and right halves; these were weighed and randomly allocated for the assay of SAMe or of -dopa, norepinephrine, and ['H]norepinephrine and its metabolites. In another type of chronic experiment, designed to determine whether idopa exerted different effects on the fate of dl-and of l-norepinephrine, the animals received 10 uCi of racemic ['H]dl-norepinephrine intracisternally and were killed 50 min after the intraperitoneal injection of "dopa or its vehicle. Essentially the same results were obtained whether l-norepinephrine or the racemic mixture was used. Whole brains were used for the assay of "dopa, norepinephrine, and tritiated compounds. Other animals received no ['H]norepinephrine but were killed 50 min or 24 hr after the last intraperitoneal injection; their brains and livers were used for the determination of SAMe concentration. Estimation of [3H]norepinephrine and metabolites Brains were homogenized in 5 volumes of ice-cold 0.4 N perchloric acid and centrifuged at 17,000 X g for 10 min. An aliquot of the supernatant fluid was used to measure the total tritium present, and the remainder was passed over alumina columns at pH 8.6 (19) . The radioactivity of unchanged ['H ]norepinephrine in the acetic acid eluate of these columns was measured (20) , and tritiated catecholdeaminated metabolites in these eluates were extracted into ethyl acetate and assayed by scintillation spectrometry (21) . The effluent and the first 5 ml of acetate-buffered wash solution from the alumina columns were combined and passed over an ion-exchange column (Dowex 50W-X4, 200-40 mesh, [H+ ] form). Tritiated, O-methylated, deaminated metabolites were collected in the effluents from these columns, and ['H]normetanephrine was then eluted from the columns with 3 N NH40H (21) .
All data thus obtained were corrected for column recoveries, determined by using ['H]norepinephrine and ['H]normetanephrine, or by utilizing fluorescence of authentic reference standards of 3,4-dihydroxymandelic acid, 3,4-dihydroxyphenylglycol, vanillylmandelic acid, and 3-methoxy,4-hydroxyphenylglycol (22) . The radioactivity in the four fractions of metabolites assayed accounted for 90-105% of the mean total tritium present in the initial brain extracts. These four fractions and their major constituents were: (i) un- Portions of the acetic acid eluate of the alumina columns were used to estimate nonradioactive norepinephrine or dopa by the method of von Euler and Lishajko (23) . This method utilizes ferricyanide oxidation to produce strongly fluorescent derivatives of norepinephrine and dopa, with different fluorescence spectra, having activation/fluorescence maxima at 395/505 and 365/495 nm, respectively (24) (25) (26) . At 395/505 nm, the relative intensity of the fluorescence produced by dopa was only 9% of that produced by norepinephrine, in (19) . Norepinephrine and dopa present were differentially estimated by measurement of the fluorescence of all samples at both sets of wavelengths (24, 26) . Dopamine produces a weakly fluorescent product upon ferricyanide oxidation. Although its activation and fluorescence maxima are the same as those of norepinephrine, its relative fluorescence intensity is only 1.5-2.0% of that produced by norepinephrine. Thus dopamine should not interfere with measurements of brain norepinephrine at the tissue concentrations encountered (19, 24) .
Estimation of S-adenosylmethionine
SAMe concentrations were measured in two ways. Usually, with tissues not contaminated with tritium (as ['H]norepinephrine or its metabolites), it was possible to use the enzymatic double-isotope-derivative, isotope-dilution assay previously reported (27) . When tissues were contaminated by tritium, a single-label modification of the usual double-label assay was used. Mean brain SAMe concentration by the single-label method was 16.6 ,ug/g, in agreement with values obtained by the double-label technique in this study and previously (27) . When catechols were added to incubation mixtures in amounts more than twice those encountered in tissues of rats treated with idopa, the estimate of tissue SAMe was found to be decreased by 6-17%. This control experiment suggests that the present assay methods are valid if the tissue concentrations of potential methyl acceptors (catechols) undergo limited increases.
RESULTS

Acute L-dopa administration
Brain norepinephrine concentration (424 + 26 ng/g brain) was significantly elevated (P < 0.05) in idopa-treated animals, when compared with "zero time" animals (298 i 9 ng/g) or with control rats killed 50 min after the intraperitoneal injection of 0.05 N HCl (296 i 8 ng/g). In i-dopa-treated animals, the brain idopa concentration at this time was 1427 ng/g, or about 3.5 times that of norepinephrine; total brain idopa represented about 0. 
The pattern of tritiated metabolites found in the brains was markedly altered by -dopa. 50 min after the final dose of -dopa on the tenth day, profound changes were evident; they were qualitatively similar to those seen in the acute experiment but much more striking. In general, concentrations of methylated products were decreased and deaminated metabolites increased ( Fig. 1 when the reduction in brain SAMe was maximal (Fig. 1 ). is converted to brain norepinephrine as long as it is available atistically significant changes are indicated by an asterisk; P to central noradrenergic neurons. Only a minute fraction lues are given in Table 1 .
of administered unlabeled -dopa or of [14C jLdopa (28) PUDopa and Brain Norepinephrine (Fig. 1) . Although the changes observed 50 min after i-dopa were quantitatively larger in chronically treated animals, their time courses suggest that they primarily reflected acute responses to the most recent dose of idopa (Fig. 1) . The competition for tissue SAMe that occurs after L4dopa administration may be of sufficient magnitude to interfere with the methylation of other compounds that are substrates for methylating enzymes; these include adrenal norepinephrine, other catechols, pineal N-acetylserotonin, fatty acids, proteins, nucleic acids, and precursors of certain phospholipids and methylated nucleic acids.
The administration of idopa produced a transient acceleration in the disappearance of intrathecally administered ['H]-norepinephrine ( Fig. 1) , followed by a slow phase of efflux at a rate similar to controls. The increase in initial disappearance rate, which is similar to that recently observed by Gershon et al. (30) , was evident only while L-dopa was detectable in the brain; it was not caused by a decrease in initial uptake of ['H]norepinephrine from the cerebrospinal fluid since the labeled amine was given before the i-dopa and since brain concentrations of ['H ]norepinephrine, 5 min after intracisternal injection, were similar in control rats and in animals chronically treated with idopa. Since there is evidence that ['H]norepinephrine is a valid label of norepinephrine in central noradrenergic neurons (1), it is likely that the increased disappearance of tracer and simultaneously increased synthesis of endogenous amine represent increased turnover of brain norepinephrine. iDopa could accelerate the disappearance of brain ['H]norepinephrine by displacement of readily releasable amine from storage sites or by acting elsewhere to modify the presynaptic input to neurons containing the labeled amine. There is some evidence that idopa (31, 32) or, more potently, its metabolites, dopamine and 3-0-methyldopamine (31), can interfere with the retention of ['H]norepinephrine at storage sites in the brain.
The changes in rat brain SAMe concentration that follow chronic i-dopa administration (Fig. 1 ) are similar to those reported after a single dose of the amino acid (16) . These decreases were observed only when the brain also contained measurable quantities of "dopa. The subsequent overshoot in brain SAMe levels is unexplained but may reflect the operation of a compensatory mechanism designed to maintain brain SAMe levels.
The effects of chronic idopa administration of hepatic SAMe differed from those in the brain. Whereas acute doses did not depress SAMe significantly, chronic administration of idopa not only lowered hepatic SAMe levels, but also produced changes lasting 24 hr. These decreases in the liver methyl donor are not readily explained, although we have evidence that the activity of the enzyme responsible for SAMe synthesis is decreased in liver after chronic idopa treatment. Thus it is possible that liver SAMe synthesis is unable to keep up with demands imposed by the rapid O-methylation required by large doses of -dopa; this interpretation can be reconciled with the observation that liver has a much larger methylating capacity than brain (27) , since brain appears to be relatively better protected than liver from demands of a large intake of the methyl acceptor. The decrease in hepatic, but not brain, SAMe after chronic Medical Sciences:
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"dopa injection may reflect other toxic effects of this treatment.
Since the intake of methionine in normal human diets is rather limited (about 30 mg/kg per day), the chronic use of "dopa could well impose excessive demands on human methylation systems, leading to the depletion of tissue methionine stores, particularly in the liver, as it attempts to keep pace with demands for SAMe synthesis. SAMe concentration has also been determined in the blood of Parkinsonian patients during the administration of L-dopa (S. Matthysse et al., to be published). Doses of L-dopa appear to produce transient decreases in SAMe concentrations, paralleling the changes observed in rat brains. Thus, it is possible that a number of important metabolic pathways utilizing SAMe as a methyl donor may also be suppressed in patients given large doses of the methyl acceptor -dopa.
